{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:56:19Z","timestamp":1791046579824,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A synthetic antimicrobial peptide was identified as a possible candidate for the development of a new antibacterial drug. The peptide, SET-M33L, showed a MIC\n                    <jats:sub>90<\/jats:sub>\n                    below 1.5\u2009\u03bcM and 3\u2009\u03bcM for\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    and\n                    <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                    , respectively. In\n                    <jats:italic>in vivo<\/jats:italic>\n                    models of\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    infections, the peptide and its pegylated form (SET-M33L-PEG) enabled a survival percentage of 60\u201380% in sepsis and lung infections when injected twice i.v. at 5\u2009mg\/Kg, and completely healed skin infections when administered topically. Plasma clearance showed different kinetics for SET-M33L and SET-M33L-PEG, the latter having greater persistence two hours after injection. Bio-distribution in organs did not show significant differences in uptake of the two peptides. Unlike colistin, SET-M33L did not select resistant mutants in bacterial cultures and also proved non genotoxic and to have much lower\n                    <jats:italic>in vivo<\/jats:italic>\n                    toxicity than antimicrobial peptides already used in clinical practice. The characterizations reported here are part of a preclinical development plan that should bring the molecule to clinical trial in the next few years.\n                  <\/jats:p>","DOI":"10.1038\/srep26077","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T05:20:01Z","timestamp":1463030401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["In vitro and in vivo efficacy, toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate"],"prefix":"10.1038","volume":"6","author":[{"given":"Jlenia","family":"Brunetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Falciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Roscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Pollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Bindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Scali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unai Cossio","family":"Arrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"G\u00f3mez-Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Quercini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Maria","family":"Rossolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Llop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Bracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"BFsrep26077_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.coph.2014.09.006","volume":"18","author":"GM Rossolini","year":"2014","unstructured":"Rossolini, G. M., Arena, F., Pecile, P. & Pollini, S. Update on the antibiotic resistance crisis. Curr Opin Pharmacol. 18, 56\u201360 (2014). Fenech (1993).","journal-title":"Curr Opin Pharmacol."},{"key":"BFsrep26077_CR2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/cid\/cit152","volume":"56","author":"HW Boucher","year":"2013","unstructured":"Boucher, H. W. et al. Infectious Diseases Society of America. 10\u2009\u00d7\u2009\u201820 Progress\u2013development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 56, 1685\u20131694 (2013).","journal-title":"Clin Infect Dis."},{"key":"BFsrep26077_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s15010-015-0749-y","volume":"43","author":"R Draenert","year":"2015","unstructured":"Draenert, R., Seybold, U., Gr\u00fctzner, E. & Bogner, J. R. Novel antibiotics: are we still in the pre-post-antibiotic era? Infection. 43, 145\u2013151 (2015).","journal-title":"Infection."},{"key":"BFsrep26077_CR4","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/nbt1267","volume":"24","author":"RE Hancock","year":"2006","unstructured":"Hancock, R. E. & Sahl, H. G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 24, 1551\u20131557 (2006).","journal-title":"Nat Biotechnol."},{"key":"BFsrep26077_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2174\/138920371408131227155308","volume":"14","author":"G Roscia","year":"2013","unstructured":"Roscia, G., Falciani, C., Bracci, L. & Pini, A. The development of antimicrobial peptides as new antibacterial drugs. Curr Protein Pept Sci. 14, 641\u2013649 (2013).","journal-title":"Curr Protein Pept Sci."},{"key":"BFsrep26077_CR6","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1096\/fj.09-145474","volume":"24","author":"A Pini","year":"2010","unstructured":"Pini, A. et al. A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo . FASEB J 24, 1015\u20131022 (2010).","journal-title":"FASEB J"},{"key":"BFsrep26077_CR7","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1128\/AAC.49.7.2665-2672.2005","volume":"49","author":"A Pini","year":"2005","unstructured":"Pini, A. et al. Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob Agents Chemother 49, 2665\u20132672 (2005).","journal-title":"Antimicrob Agents Chemother"},{"key":"BFsrep26077_CR8","doi-asserted-by":"publisher","first-page":"5409","DOI":"10.1073\/pnas.85.15.5409","volume":"85","author":"JP Tam","year":"1988","unstructured":"Tam, J. P. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 85, 5409\u20135413 (1988).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep26077_CR9","doi-asserted-by":"publisher","first-page":"46590","DOI":"10.1074\/jbc.M308615200","volume":"278","author":"L Bracci","year":"2003","unstructured":"Bracci, L. et al. Synthetic peptides in the form of dendrimers become resistant to protease activity. J Biol Chem 278, 46590\u201346595 (2003).","journal-title":"J Biol Chem"},{"key":"BFsrep26077_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1747-0285.2007.00487.x","volume":"69","author":"C Falciani","year":"2007","unstructured":"Falciani, C. et al. Molecular basis of branched peptide resistance to enzyme proteolysis. Chem Biol Drug Des 69, 216\u2013221 (2007a).","journal-title":"Chem Biol Drug Des"},{"key":"BFsrep26077_CR11","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1158\/1535-7163.MCT-07-0164","volume":"6","author":"C Falciani","year":"2007","unstructured":"Falciani, C. et al. Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting. Mol Cancer Ther 6, 2441\u20132448 (2007b).","journal-title":"Mol Cancer Ther"},{"key":"BFsrep26077_CR12","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2174\/138920308785915227","volume":"9","author":"A Pini","year":"2008","unstructured":"Pini, A., Falciani, C. & Bracci, L. Branched peptides as therapeutics. Curr Protein Pept Sci 9, 468\u2013477 (2008).","journal-title":"Curr Protein Pept Sci"},{"key":"BFsrep26077_CR13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2174\/156800910793605875","volume":"10","author":"C Falciani","year":"2010","unstructured":"Falciani, C. et al. Modular branched neurotensin peptides for tumor target tracing and receptor-mediated therapy: a proof-of-concept. Curr Cancer Drug Targets 10, 695\u2013704 (2010).","journal-title":"Curr Cancer Drug Targets"},{"key":"BFsrep26077_CR14","doi-asserted-by":"publisher","first-page":"173507","DOI":"10.1155\/2015\/173507","volume":"2015","author":"J Brunetti","year":"2015","unstructured":"Brunetti, J. et al. Neurotensin branched peptide as a tumor-targeting agent for human bladder cancer. Biomed Res Int. 2015, 173507 (2015).","journal-title":"Biomed Res Int"},{"key":"BFsrep26077_CR15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/psc.858","volume":"13","author":"A Pini","year":"2007","unstructured":"Pini, A. et al. Characterization of the branched antimicrobial peptide M6 by analyzing its mechanism of action and in vivo toxicity. J Pept Sci 13, 393\u2013399 (2007).","journal-title":"J Pept Sci"},{"key":"BFsrep26077_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00726-011-1103-z","volume":"43","author":"A Pini","year":"2012","unstructured":"Pini, A. et al. Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions. Amino Acids 43, 467\u2013473 (2012).","journal-title":"Amino Acids"},{"key":"BFsrep26077_CR17","doi-asserted-by":"publisher","first-page":"e46259","DOI":"10.1371\/journal.pone.0046259","volume":"7","author":"C Falciani","year":"2012","unstructured":"Falciani, C. et al. Isomerization of an antimicrobial peptide broadens antimicrobial spectrum to gram-positive bacterial pathogens. PLoS One 7, e46259 (2012).","journal-title":"PLoS One"},{"key":"BFsrep26077_CR18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s00726-014-1686-2","volume":"46","author":"C Falciani","year":"2014","unstructured":"Falciani, C. et al. Site-specific pegylation of an antimicrobial peptide increases resistance to Pseudomonas aeruginosa elastase. Amino Acids. 46, 1403\u20131407 (2014).","journal-title":"Amino Acids."},{"key":"BFsrep26077_CR19","doi-asserted-by":"publisher","first-page":"e00021","DOI":"10.1128\/mBio.00021-13","volume":"4","author":"BA Napier","year":"2013","unstructured":"Napier, B. A. et al. Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii. MBio. 4, e00021\u201313 (2013).","journal-title":"MBio."},{"key":"BFsrep26077_CR20","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1128\/AAC.03937-14","volume":"59","author":"B Deslouches","year":"2015","unstructured":"Deslouches, B. et al. Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens. Antimicrob Agents Chemother. 59, 1329\u20131333 (2015).","journal-title":"Antimicrob Agents Chemother."},{"key":"BFsrep26077_CR21","doi-asserted-by":"publisher","first-page":"5521","DOI":"10.1128\/AAC.01480-13","volume":"57","author":"A Cannatelli","year":"2013","unstructured":"Cannatelli, A. et al. In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ\/PhoP mgrB regulator. Antimicrob Agents Chemother. 57, 5521\u20135526 (2013).","journal-title":"Antimicrob Agents Chemother."},{"key":"BFsrep26077_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1179\/joc.2009.21.Supplement-1.5","volume":"21","author":"G Nicoletti","year":"2009","unstructured":"Nicoletti, G., Nicolosi, D., Rossolini, G. M. & Stefani, S. Intra-abdominal infections: etiology, epidemiology, microbiological diagnosis and antibiotic resistance. J Chemother. 21 Suppl 1, 5\u201311 (2009).","journal-title":"J Chemother."},{"key":"BFsrep26077_CR23","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/QCO.0b013e32835635cb","volume":"25","author":"YH Chen","year":"2012","unstructured":"Chen, Y. H. & Hsueh, P. R. Changing bacteriology of abdominal and surgical sepsis. Curr Opin Infect Dis. 25, 590\u2013595 (2012).","journal-title":"Curr Opin Infect Dis."},{"key":"BFsrep26077_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/MCP.0b013e32835f1afc","volume":"19","author":"O Ciofu","year":"2013","unstructured":"Ciofu, O., Hansen, C. R. & H\u00f8iby, N. Respiratory bacterial infections in cystic fibrosis. Curr Opin Pulm Med. 19, 251\u2013258 (2013).","journal-title":"Curr Opin Pulm Med."},{"key":"BFsrep26077_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2165\/11539770-000000000-00000","volume":"12","author":"DC Wu","year":"2011","unstructured":"Wu, D. C., Chan, W. W., Metelitsa, A. I., Fiorillo, L. A. & Lin, N. Pseudomonas skin infection: clinical features, epidemiology, and management. Am J Clin Dermatol. 12, 157\u201369 (2011).","journal-title":"Am J Clin Dermatol."},{"key":"BFsrep26077_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1586\/ers.12.39","volume":"6","author":"K Jain","year":"2012","unstructured":"Jain, K. & Smyth, A. R. Current dilemmas in antimicrobial therapy in cystic fibrosis. Expert Rev Respir Med. 6, 407\u2013422 (2012).","journal-title":"Expert Rev Respir Med."},{"key":"BFsrep26077_CR27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1586\/eri.13.12","volume":"11","author":"LN Pendleton","year":"2013","unstructured":"Pendleton, L. N., Gorman, S. P. & Gilmore, B. F. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther. 11, 297\u2013308 (2013).","journal-title":"Expert Rev Anti Infect Ther."},{"key":"BFsrep26077_CR28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2146\/ajhp060473","volume":"64","author":"TM Arnold","year":"2007","unstructured":"Arnold, T. M., Forrest, G. N. & Messmer K. J. Polymyxin antibiotics for gram-negative infections. Am. J. Health. Syst. Pharm. 64, 819\u2013826 (2007).","journal-title":"Am. J. Health. Syst. Pharm"},{"key":"BFsrep26077_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ccc.2007.12.003","volume":"24","author":"A Michalopoulos","year":"2008","unstructured":"Michalopoulos, A. & Falagas, M. E. Colistin and polymyxin B in critical care. Crit. Care Clin. 24, 377\u2013391 (2008).","journal-title":"Crit. Care Clin."},{"key":"BFsrep26077_CR30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1586\/eri.12.78","volume":"10","author":"S Biswas","year":"2012","unstructured":"Biswas, S., Brunel, J. M., Dubus, J. C., Reynaud-Gaubert, M. & Rolain, J. M. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 10, 917\u2013934 (2012).","journal-title":"Anti Infect Ther"},{"key":"BFsrep26077_CR31","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1086\/429323","volume":"40","author":"ME Falagas","year":"2005","unstructured":"Falagas, M. E. & Kasiakou, S. K. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis. 40, 1333\u20131341 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep26077_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40560-015-0072-9","volume":"3","author":"M Gurjar","year":"2015","unstructured":"Gurjar, M. Colistin for lung infection: an update. J Intensive Care. 3, 3 (2015).","journal-title":"J Intensive Care"},{"key":"BFsrep26077_CR33","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1128\/AAC.04998-14","volume":"59","author":"A Cannatelli","year":"2015","unstructured":"Cannatelli, A., Santos-Lopez, A., Giani, T., Gonzalez-Zorn, B. & Rossolini, G. M. Polymyxin resistance caused by mgrB inactivation is not associated with significant biological cost in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 59, 2898\u20132900 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep26077_CR34","unstructured":"CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard-Tenth Edition. CLSI document M07-A10. Wayne, PA (2015)."},{"key":"BFsrep26077_CR35","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00018-013-1291-7","volume":"70","author":"V Luca","year":"2013","unstructured":"Luca, V., Stringaro, A., Colone, M., Pini, A. & Mangoni, M. L. Esculentin(1-21), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa. Cell Mol Life Sci. 70, 2773\u20132786 (2013).","journal-title":"Cell Mol Life Sci."},{"key":"BFsrep26077_CR36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nprot.2006.26","volume":"1","author":"KH Choi","year":"2006","unstructured":"Choi, K. H. & Schweizer, H. P. Mini-Tn7 insertion in bacteria with secondary, non-glmS-linked attTn7 sites: example Proteus mirabilis HI4320. Nat Protoc. 1, 170\u2013178 (2006).","journal-title":"Nat Protoc."},{"key":"BFsrep26077_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0165-1161(85)90015-9","volume":"147","author":"M Fenech","year":"1985","unstructured":"Fenech, M. & Morley, A. A. Measurement of micronuclei in lymphocytes. Mutat Res. 147, 29\u201336 (1985).","journal-title":"Mutat Res."},{"key":"BFsrep26077_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0027-5107(93)90049-L","volume":"285","author":"M Fenech","year":"1993","unstructured":"Fenech, M. The cytokinesis-block micronucleus technique: a detailed description of the method and its application to genotoxicity studies in human populations. Mutat Res. 285, 35\u201344 (1993).","journal-title":"Mutat Res."},{"key":"BFsrep26077_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 18, 268\u20132681 (2012).","journal-title":"Clin Microbiol Infect."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep26077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep26077","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep26077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T23:29:48Z","timestamp":1672874988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep26077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,12]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,5,31]]}},"alternative-id":["BFsrep26077"],"URL":"https:\/\/doi.org\/10.1038\/srep26077","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,12]]},"assertion":[{"value":"11 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patents covering the intellectual property of peptide SET-M33 are owned by or licensed to SetLance. Chiara Falciani, Alessandro Pini and Luisa Bracci are partners of SetLance. The authors declare that they have no other competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26077"}}